Heretic
Compound

GlyNAC and glutathione precursors

Small trials look good, but almost all the human data comes from one lab.

Updated 14 Oct 20268 sources9 min read
Short answer

GlyNAC pairs glycine and N-acetylcysteine, the two precursors needed to make glutathione, which declines with age. A 16-week randomized trial in 24 older adults corrected glutathione deficiency and improved oxidative stress, insulin resistance, inflammation and walking speed, with smaller pilots showing similar metabolic effects in diabetes. Nearly all human data comes from the Baylor/Sekhar group, and benefits faded within 12 weeks of stopping, so independent replication is the missing piece.

Summary drafted from this entry’s sources; editorial review pending.

01Key questions

Has GlyNAC been tested in humans?

Yes. The main trial is a 16-week double-blind RCT in 24 older adults that corrected glutathione deficiency and improved oxidative stress, insulin resistance, inflammation, endothelial function and gait speed, backed by smaller pilots in older adults and type 2 diabetes.2

Does GlyNAC work for aging?

Human trials show improvement in aging-associated markers like oxidative stress, inflammation and physical function, but no trial has tested hard endpoints such as lifespan, falls or hospitalization. Mice lived 24% longer on GlyNAC, which is animal data only.27

Does glycine or NAC alone work as well?

Probably not. Aging creates a glycine bottleneck on top of the cysteine one, so the pair restores glutathione synthesis better than either alone in the cited work.1

Is GlyNAC safe?

Both components are GRAS with long human safety records, and trials reported good tolerability. One caveat in the body: NAC can act as a pro-oxidant immediately after acute injury.5

What would change this rating?

Independent replication outside the Baylor group, trials longer than a year, and the first randomized trial directly testing GlyNAC plus structured exercise, which the 2026 review names as the key missing study.1

02Overview

GlyNAC (glycine + N-acetylcysteine) targets glutathione (GSH) deficiency, a hallmark of aging linked to oxidative stress, mitochondrial dysfunction, inflammation, endothelial dysfunction, insulin resistance, and sarcopenia/frailty. Multiple small RCTs and pilots from the Baylor/Sekhar group and collaborators consistently show reversal of age-associated defects across mitochondrial, metabolic, inflammatory, cognitive, and physical domains. Synergistic precursor approach outperforms single-agent supplementation; low-cost, oral, GRAS status supports longevity clinic adoption.

A May 2026 comprehensive review in Frontiers in Nutrition (Wang et al., PMID 42232577) consolidates the human and preclinical evidence and frames GlyNAC + exercise as a candidate paradigm for mitigating sarcopenia and frailty. PMID 42232577 is now the highest-yield single source for practitioners.

03Key Human Evidence (RCTs and Pilots)

Landmark Baylor RCT (Kumar/Sekhar 2023)

  • Design: 16-week double-blind RCT, n=24 older adults (OA) + 12 young adults (YA). GlyNAC (glycine 1.33 mmol/kg/d + NAC 0.83 mmol/kg/d ≈ 100 mg/kg/d each) vs. isonitrogenous alanine placebo in OA; YA received open-label GlyNAC.
  • Outcomes: Corrected GSH deficiency (RBC, muscle), reduced oxidative stress (MDA, 4-HNE), improved mitochondrial fatty-acid oxidation (MFO), lowered inflammation (IL-6, TNF-α), improved endothelial function (flow-mediated dilation), reduced insulin resistance (HOMA-IR), improved physical function (gait speed, muscle strength, 6-min walk), and multiple aging hallmarks. Safe and well-tolerated.
  • Citation: Kumar P et al. J Gerontol A Biol Sci Med Sci. 2023;78(1):75-89. PMID 35975308. NCT01870193. (Cited 121+ times as of mid-2026.)

Pilot Open-Label Trial (Kumar/Sekhar 2021)

  • Design: 36-week open-label, 8 OA + 8 YA. GlyNAC x 24 weeks → 12-week withdrawal.
  • Outcomes: 24-week GlyNAC corrected GSH, ↓ oxidative stress, ↓ insulin resistance, ↓ inflammation, ↑ cognition (MoCA, Trail-Making), ↑ muscle strength and gait speed, ↓ body fat. Effects declined after withdrawal — sustained supplementation required.
  • Citation: Kumar P et al. Clin Transl Med. 2021;11(10):e372. doi 10.1002/ctm2.372.

Glucose-Challenge RCT (Sekhar 2022, conference paper; full data in 2023 paper above)

  • Design: 75-g oral glucose load before/after 16-week GlyNAC vs. placebo (20 OA + 10 YA).
  • Outcomes: OA showed exaggerated postprandial oxidative stress (TBARS +5.6% vs. −0.1% YA, P<0.0001) and inflammation (IL-6 +11.2 vs. +3.5, P<0.0001). GlyNAC blunted both (OxS −0.4%, IL-6 4.2%); placebo no effect.
  • Citation: Sekhar R, Taffet G, Kumar P. Innov Aging 2022;6:814 (Gerontological Society conference proceedings).

Type 2 Diabetes Pilot (Sekhar 2022)

  • Design: 14-day open-label, 10 T2D + 10 non-diabetic controls.
  • Outcomes: T2D showed 36% lower MFO, 106% higher MGO, 425% greater HOMA-IR, 76% higher plasma FFA at baseline (all P<0.05 vs. controls). After 14 days GlyNAC: MFO +30% (P<0.001), MGO −47% (P<0.01), HOMA-IR −22% (P<0.01), FFA −25% (P<0.01). Largest metabolic effect sizes from any GSH precursor trial in T2D.
  • Citation: Sekhar RV. Antioxidants. 2022;11(1):154. doi 10.3390/antiox11010154.

Doses in studies

  • Outcomes: No significant change in total GSH or GSH:GSSG in full cohort. Post-hoc: high-OxS + low-GSH subgroup showed ↑ GSH generation (905.4 vs. 819.7 mg/L, P=0.016). GlyNAC raised fasting glycine levels.
  • Citation: Lizzo G et al. Front Aging. 2022;3:852569. PMID 35821844; PMCID PMC9261343.

"Brain Glucose Steal" 2024 Conference Update

  • Design: Sekhar/Kumar 2024 — extending the 2021 pilot with brain-specific outcomes and the "brain glucose steal" finding.
  • Key Finding: Impaired peripheral mitochondrial function diverts glucose away from the brain in aging ("brain glucose steal"), linked to reduced brain energy availability and cognitive decline. GlyNAC corrected peripheral mitochondrial dysfunction and restored brain glucose utilization alongside cognitive improvement.
  • Citation: Sekhar R et al. Innov Aging 2024;8(Suppl 1):250. doi 10.1093/geroni/igae098.0809.

2026 Review (Wang et al., Front Nutr)

  • Key framing: GlyNAC + exercise is presented as a candidate paradigm for mitigating multiple aging hallmarks. Includes dedicated tables on NAC + exercise (16-trial summary) and GlyNAC animal/human outcomes.
  • Citation: Wang X, Hou R, Chen Z, Wang X, Wang H. Front Nutr. 2026;13:1775264. PMID 42232577; PMCID: PMC13223053. (Independent academic group, China — not Baylor.)

04Evidence Separation

Human RCTs/pilots (positive, small cohorts): GlyNAC combination consistently outperforms placebo in OA across: - Glutathione restoration (RBC, muscle) - Oxidative stress markers (MDA, 4-HNE, TBARS) - Mitochondrial fatty-acid oxidation - Insulin sensitivity (HOMA-IR) - Endothelial function (FMD) - Inflammation (IL-6, TNF-α) - Cognition (MoCA, Trail-Making, BDNF) - Physical function (gait speed, grip strength, 6-min walk) - Body composition (fat mass, lean mass)

PMID 35975308 is the landmark trial. PMID 42232577 (2026 review) and the Sekhar 2024 conference update extend to brain and postprandial contexts.

Animal/preclinical (Sekhar group + others): - Aged C57BL/6J mice: GlyNAC extended lifespan by 24%, improved mitophagy/nutrient sensing, lowered oxidative stress, genomic damage (PMID 35268089). - Brain aging: GlyNAC reversed age-associated cognitive decline in old mice, restored brain GSH, mitochondrial function, glucose uptake, neurotrophic factors (Kumar/Osahon/Sekhar 2023, Antioxidants 12:1042, doi 10.3390/antiox12051042). - Cardiac aging: NAC+glycine (not NAC alone) improved diastolic function, lowered atrial volume/diastolic pressure, decreased leukocyte infiltration, upregulated mitochondrial genes, restored ATP in 30-month-old mice (Cieslik/Sekhar 2018, J Gerontol A). - COPD-like exercise studies suggest redox restoration is consistent across tissues.

Glycine alone: Supportive longevity data (observational cohorts; Khaw et al. — higher intake linked to lower mortality). Lustgarten 2013 PLoS ONE: higher serum glycine → lower insulin resistance, lower central adiposity in functionally-limited OA. Soh 2024 GeroScience systematic review: glycine alters physiological system characteristics in adults but trials in OA remain limited.

NAC alone: - Mixed; historical FDA import alerts (2020-2024) on compounded forms; precursors remain accessible. - Exercise evidence shows context-dependence (see 2026 review, Front Nutr Section 5). - Benefits most pronounced in low-baseline-GSH individuals (Paschalis 2018, Free Radic Biol Med — VO2max +13.6%, time-trial +15.4%, Wingate +11.4% only in low-GSH subgroup). - Pro-oxidant risk under acute inflammation (Childs 2001, Free Radic Biol Med — NAC+vitamin C increased lipid hydroperoxides and CK/LDH after eccentric injury). - COPD combination trial (Ebrahimi Samarin 2025, J Appl Health Stud Sport Physiol

Liposomal glutathione: Bioavailability concerns; less evidence vs. precursors.

Gaps: Larger long-term RCTs (>1 year), head-to-head vs. other mitochondrial agents (MOTS-c, SS-31), optimal dosing in GLP-1 users, pediatric/young adult data sparse, independent replication outside Baylor group pending.

05Mechanisms (Consolidated)

The 2026 Frontiers in Nutrition review (PMID 42232577, Section 6.1) organizes the mechanisms into four interacting axes that map onto hallmarks of aging:

  1. Dual precursor bottleneck for GSH synthesis. Aging muscle suffers severe intracellular GSH depletion. While cysteine (from NAC) is the canonical rate-limiting precursor, advanced aging creates a secondary glycine bottleneck. GlyNAC uniquely overcomes both, maximizing GSH synthesis rate.
  2. Mitochondrial protection and mitophagy restoration. GSH shields mitochondria from self-generated ROS; restored GSH improves respiratory capacity/ATP output and enables mitophagy of dysfunctional organelles that accumulate in aged muscle (Kumar 2022 Nutrients, PMID 35268089).
  3. NF-κB suppression and anti-catabolic shift. Chronic low-grade inflammation activates NF-κB → upregulates muscle-specific E3 ubiquitin ligases Atrogin-1 and MuRF1 → muscle protein breakdown. GlyNAC's redox restoration + glycine's direct cytokine-suppressive effects blunt NF-κB, shifting muscle microenvironment from catabolic to anabolic. Glycine is the smallest anti-inflammatory micronutrient (Aguayo-Cerón 2023, Int J Mol Sci 24:11236).
  4. Anabolic-resistance mitigation via mTOR protection. Aging muscle is less responsive to mechanical loading (exercise) and protein ingestion. The antioxidant shield from GlyNAC prevents ROS interference with mTOR signaling post-exercise → facilitates muscle protein synthesis (MPS) response. Explains clinical grip-strength, gait-speed, and 6-min walk improvements.

Additional supporting mechanisms (cited in PMID 42232577): - Collagen synthesis (glycine is the most abundant residue in collagen → intramuscular connective tissue, fascia, tendon integrity — relevant for force transmission in frail elders). - Creatine synthesis via glycine amidinotransferase (ATP buffer during contraction). - Direct anti-inflammatory action in macrophages (glycine inhibits IL-6, TNF-α production). - "Brain glucose steal" reversal (Sekhar 2024 Innov Aging conference): peripheral mitochondrial dysfunction in aging diverts glucose from brain; GlyNAC restores peripheral mito function → restores brain glucose utilization → cognitive improvement.

06GlyNAC + Exercise (2026 Framing)

The Wang et al. 2026 review (PMID 42232577) explicitly positions GlyNAC as a synergistic adjunct to structured exercise in older adults:

  • Exercise alone (resistance + aerobic) blunts with age due to anabolic resistance, chronic inflammation, and impaired redox. GlyNAC restores the redox/mitochondrial substrate so exercise adaptations can fully manifest.
  • Mechanistic logic: GlyNAC protects mTOR from ROS interference → stronger MPS after resistance training. Blunts post-exercise inflammation blunting. Restores mitochondrial biogenesis response to aerobic stimuli.
  • Open gap acknowledged: No published RCT directly testing GlyNAC + structured exercise in OA. Inference is from mechanism + parallel single-modality data. Highest-quality design awaiting.
  • Related amino-acid-exercise RCTs reviewed in same paper: citrulline+leucine (Kim 2021, sarcopenic women), soy peptides (Imaoka 2022, cognition additive to exercise), HMB+arginine+lysine (Flakoll 2004, functionality + grip), whey > collagen during inactivity (Oikawa 2018, Am J Clin Nutr).

07Doses in studies

From clinical trials + 2026 review synthesis:

Context Glycine NAC Source
Baylor/Sekhar landmark RCT — — PMID 35975308
T2D pilot (Sekhar 2022) ~1.33 mmol/kg/d ~0.83 mmol/kg/d doi 10.3390/antiox11010154
Lizzo dose-finding — — PMID 35821844
Clinical/community practice — — Inferred from trials + clinic reporting

Swipe table →

Notes on the evidence: - The clinical benefits come from the Baylor trials, which used about 100 mg/kg/day each of glycine and NAC (roughly 7–10 g/day each), well above typical commercial amounts. - In an exercise study, oral NAC at 70 mg/kg raised thiol status without GI effects, while 140 mg/kg or more increased nausea and bloating (Ferreira 2011, Int J Sport Nutr Exerc Metab). - Sustained supplementation required — withdrawal trials show benefit loss within 12 weeks. - Baseline GSH/OxS stratification predicts response (Paschalis 2018, PMID 35821844 subgroup analyses). - NAC timing relative to acute inflammation matters — can act as pro-oxidant immediately post-injury (Childs 2001). - Both compounds GRAS; long human safety record in acetaminophen overdose (NAC IV).

08Commercial Opportunity

Claims-audit guidance for clinic marketing: - Legitimate: GSH restoration, oxidative stress reduction, mitochondrial support, insulin sensitivity, endothelial function, exercise-recovery support (RCT-supported). - Speculative: lifespan extension (only animal data), hard clinical endpoints like falls/hospitalization (no human hard-endpoint RCTs). - Mechanism-misuse risk: avoid claiming "anti-aging" without specifying the specific hallmarks addressed.

What studies and practitioners report

Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.

  • Trial 100 mg/kg, 7-10 g · Baylor/Sekhar landmark RCT older adults (RCT) PMID 35975308
  • Trial 1.2-3.6 g · Lizzo dose-finding healthy adults (dose-finding trial) PMID 35821844
  • Trial 3 g · Glycine before bed healthy adults under sleep restriction PMID 22529837

09Connections

Neighborhood · 2 linked entriesOpen full map →
Hallmarks of agingMechanism · 17 links→ Heavy metals and chelationTherapy · 7 links→

10Sources

  1. Wang X, Hou R, Chen Z, Wang X, Wang H. Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging. Front Nutr. 2026;13:1775264. PMID 42232577 ; PMCID: PMC13223053 .PubMed 42232577 · PMC13223053
  2. Kumar P et al. (Sekhar group). J Gerontol A Biol Sci Med Sci. 2023;78(1):75-89. PMID 35975308 . PMC9879756 . NCT01870193 .PubMed 35975308 · NCT01870193 · PMC9879756
  3. DOI 10.1002/ctm2.372DOI 10.1002/ctm2.372
  4. DOI 10.3390/antiox11010154DOI 10.3390/antiox11010154
  5. Lizzo G et al. Front Aging. 2022;3:852569. PMID 35821844 . PMC9261343 .PubMed 35821844 · PMC9261343
  6. DOI 10.1093/geroni/igae098.0809DOI 10.1093/geroni/igae098.0809
  7. Kumar P, Osahon OW, Sekhar RV. GlyNAC supplementation in mice extends lifespan. Nutrients 2022;14(5):1114. PMID 35268089 . PMC8912885 .PubMed 35268089 · PMC8912885
  8. Kumar P, Osahon OW, Sekhar RV. GlyNAC reverses age-associated cognitive decline in mice. Antioxidants 2023;12(5):1042. doi 10.3390/antiox12051042 .DOI 10.3390/antiox12051042

11Entry history

Latest content update.

Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.